A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004
·
clinicaltrials.gov ↗
PHASE3
Phase
ACTIVE_NOT_RECRUITING
Status
1300
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Sclerosis
Interventions
DRUG:
Ocrelizumab
Sponsor
Hoffmann-La Roche